Genomic profiling of Mycosis Fungoides identifies patients at high risk of disease progression.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
21 Mar 2024
Historique:
accepted: 17 02 2024
received: 12 12 2023
revised: 15 02 2024
medline: 21 3 2024
pubmed: 21 3 2024
entrez: 21 3 2024
Statut: aheadofprint

Résumé

Mycosis fungoides (MF) is the most prevalent primary cutaneous T-cell lymphoma, with an indolent or aggressive course and poor survival. The pathogenesis of MF remains unclear, and prognostic factors in the early stages are not well-established. Here, we characterized the most recurrent genomic alterations using whole-exome sequencing of 67 samples from 48 patients from Lille University Hospital (France), including 18 sequential samples drawn across stages of the malignancy. Genomic data were analyzed on the Broad Institute's Terra bioinformatics platform. We found that gain7q, gain10p15.1 (IL2RA and IL15RA), del10p11.22 (ZEB1), or mutations in JUNB and TET2 are associated with high-risk disease stages. Furthermore, gain7q, gain10p15.1 (IL2RA and IL15RA), del10p11.22 (ZEB1), and del6q16.3 (TNFAIP3) are coupled with shorter survival. Del6q16.3 (TNFAIP3) was a risk factor for progression in low-risk patients. By analyzing the clonal heterogeneity and the clonal evolution of the cohort, we defined different phylogenetic pathways of the disease with acquisition of JUNB, gain10p15.1 (IL2RA and IL15RA), or del12p13.1 (CDKN1B) at progression. These results establish the genomics and clonality of MF and identify potential patients at risk of progression, independent of their clinical stage.

Identifiants

pubmed: 38513135
pii: 515386
doi: 10.1182/bloodadvances.2023012125
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Society of Hematology.

Auteurs

Léa Fléchon (L)

Canther, INSERM UMR-S1277, CNRS UMR9020, Lille University, Lille, France.

Inès Arib (I)

Canther, INSERM UMR-S1277, CNRS UMR9020, Lille University, Lille, France.

Ankit K Dutta (AK)

Dana-Farber Cancer Institute, Boston, Massachusetts, United States.

Romanos Sklavenitis-Pistofidis (R)

Dana-Farber Cancer Institute, Boston, Massachusetts, United States.

Remi Tilmont (R)

CHRU Lille, Lille, France.

Chip Stewart (C)

Broad Institute, Cambridge, Massachusetts, United States.

Romain Dubois (R)

CHRU de Lille, Lille, France.

Stéphanie Poulain (S)

CHRU de Lille, Lille, France.

Marie-Christine Copin (MC)

CHU Angers, ANGERS, France.

Sahir Javed (S)

CH Valenciennes, Valenciennes, France.

Morgane Nudel (M)

CHRU Lille, Lille, France.

Nicolas Gower (N)

CHU Lille, Lille, France.

Nicolas Gazeau (N)

CHU-Lille, Lille, France.

Cynthia Saade (C)

CHU Lille, Lille, France.

Marietou Binta Thiam (MB)

CHU Lille, Lille, France.

Sarah Faiz (S)

CHRU de Lille, Lille, France.

Olivier Carpentier (O)

CH Roubaix, Roubaix, France.

Laurent Mortier (L)

Claude Huriez University Hospital, Lille, France.

Martin Figeac (M)

Lille University, Lille, France.

Bruno Quesnel (B)

CHU Lille, Lille, France.

Suman Mitra (S)

UMR 9020-UMR-S 1277-Canther, Institut de Recherche contre le Cancer de Lille, University Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France, Lille, France.

Franck Morschhauser (F)

University of Lille, Lille, France.

Gad Getz (G)

Broad Institute, Mass General Hospital, Cambridge, Massachusetts, United States.

Irene M Ghobrial (IM)

Dana-Farber Cancer Institute, Boston, Massachusetts, United States.

Salomon Manier (S)

Canther, INSERM UMR-S1277, CNRS UMR9020, Lille University, Lille, France.

Classifications MeSH